Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Sun Pharma Introduces ILUMYA in India, Expanding Access to Advanced Psoriasis Treatment
With this launch, Sun Pharma aims to strengthen advanced dermatology care in the country and provide a much-needed therapy option for individuals living with difficult-to-treat psoriasis.
- By Newsdesk
- New Delhi
- Dec 01, 2025
Sun Pharmaceutical Industries has launched ILUMYA (tildrakizumab) in India, bringing a globally recognised biologic therapy for moderate-to-severe plaque psoriasis to domestic patients. The rollout marks an important milestone in India’s dermatology landscape, offering a targeted, long-term treatment option for a chronic and often debilitating skin condition.
ILUMYA is designed to inhibit IL-23 by selectively targeting its p19 subunit, helping reduce the inflammation that triggers the formation of thick, scaly patches on the skin. The drug is already approved in 35 countries, including major markets such as the United States, and its India launch aligns with Sun Pharma’s strategy to expand access to its specialty medicines portfolio.
The introduction of ILUMYA in India follows a clinical study conducted on 115 Indian patients. At week 28 of treatment, nearly 94% of participants achieved at least 75% improvement in skin clearance (PASI 75), while over 78% demonstrated 90% clearance (PASI 90). The therapy also showed strong tolerability, with no cases of immunogenicity reported.
For Indian patients grappling with moderate-to-severe psoriasis — a condition that can significantly impact quality of life - ILUMYA offers a promising solution. Its targeted biologic approach provides a sustained and effective alternative to conventional therapies, which often come with limitations in long-term efficacy or safety.
With this launch, Sun Pharma aims to strengthen advanced dermatology care in the country and provide a much-needed therapy option for individuals living with difficult-to-treat psoriasis.